ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PHAT vs MPLT // NET PROFIT MARGIN

Phathom Pharmaceuticals Inc. (NASDAQ) VS. MapLight Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 3 — MPLT 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. MPLT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PHAT MPLT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.40% -2.60 MPLT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin ACTIVE -0.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.5 31.5 +2.02 PHAT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $503.2M $500.1M $3.2M PHAT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PHAT REV MPLT REV PHAT GROSS % MPLT GROSS % PHAT FCF MPLT FCF
FY 2025 $175.1M $0 87.1% — -$167.0M -$138.6M
FY 2024 $55.3M $0 85.6% — -$266.9M -$79.6M
FY 2023 $682.0K — — — -$137.6M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
MPLT // BETA —